Expert Panel Maps the Hidden Variables That Could Skew CAR-T Comparisons in Lymphoma
A two-round expert elicitation among German and Austrian hematologists has produced a consensus list of prognostic factors and treatment-effect modifiers ...
Tag: cytokine release syndrome
Two Immune Cell Armies in One Infusion: Combination NK and T Cell Therapy Shows Promise in Hard-to-Treat Tumors
A phase 1 trial found that an autologous combination of natural killer cells and tumor-primed T lymphocytes was safe and ...
Nivolumab Can Trigger Deadly Cytokine Storm, Largest Case Review Finds
A retrospective review of 35 published cases shows that nivolumab can trigger cytokine release syndrome weeks to months into treatment, ...
Taming the Cytokine Storm: How Doctors Are Making CAR T-Cell Therapy Safer
A comprehensive new review maps how clinicians are taming cytokine release syndrome, the most dangerous side effect of CAR T-cell ...
Living With Relapsed Multiple Myeloma: A Patient’s Journey Through Talquetamab and Team-Based Care
A new first-person perspective in Advances in Therapy follows a music professor through repeated myeloma relapses to talquetamab therapy, revealing ...
Engineered T Cells Targeting Hepatitis B Antigen Show Glimmer of Benefit in Advanced Liver Cancer
A case report details how HBsAg-targeted TCR-engineered T cells produced a manageable grade 3 cytokine release syndrome and a transient ...
CAR-T Cell Therapy Pushes Beyond Blood Cancers Into Solid Tumors and Autoimmune Disease
A sweeping review charts how CAR-T cell therapy has evolved from a blood cancer breakthrough into a versatile platform tackling ...
Second CAR T-Cell Infusion Hits Myeloma After CELMoD Bridging
A German case report describes rapid deep response to ciltacabtagene autoleucel as a second BCMA-directed CAR T-cell therapy after mezigdomide-based ...
Subcutaneous Tarlatamab Shows Safety and Early Activity in Small Cell Lung Cancer
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
Longer Gaps Between Tarlatamab Doses Show Promise in Small Cell Lung Cancer
The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!